Jaguar Health Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Consolidated Net Revenue Quarterly20.3MTarget: Growth driven by licensing and milestone payments
License and Grant Revenue Quarterly19.1MTarget: Up to $38 million in non-dilutive funds from Woodward/Future Pak agreement
Income from Operations Quarterly10.2MTarget: Maintain positive operating income through strategic out-licensing
Watch Items
- NDA Filing for Liquid Oral Crofelemer in MVIDTrigger: Mid-2027 target filing dateAction: Compile and submit clinical data from the active-treatment extension phase of the pediatric MVID trial.
- Nasdaq Bid Price ComplianceTrigger: Maintain closing bid price above $1.00Action: Monitor stock price post the 1-for-35 reverse stock split executed on April 30, 2026.
- Phase 2 SBS-IF Clinical Trial CompletionTrigger: Completion of blinded trial in short bowel syndromeAction: Track patient enrollment and clinical outcomes to support future regulatory filings.
Research as of 20 Jun 2026